Drug Database
BO

botulinum toxin type A (Coretox)

✓ Approved

Medytox · therapeutic agent

What is botulinum toxin type A?

botulinum toxin type A is a therapeutic agent developed by Medytox. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesCoretox
CompanyMedytox
RouteInjectable (Others)
StatusApproved

Therapeutic Indications

botulinum toxin type A is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersSkin wrinkling✓ Approved
Musculoskeletal and connective tissue disordersMuscle spasmsPhase III

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedJournal of affective disorders2026-08-30

Antidepressant effects of facial botulinum toxin a injections: Insights from randomized controlled trials.

Gao Zhengyu Z, Chen Xiaoqin X, Yu Xiaoming X, Hu Luoman L et al.

Depressive disorders cause significant global disability, yet oral antidepressants often have systemic side effects and delayed onset. This systematic review and meta-analysis evaluated the efficacy and safety of facial injections of Botulinum toxin A (BoNT/A) compared with placebo and the active antidepressant sertraline. We searched PubMed, Embase, Cochrane CENTRAL, Web of Science, and PsycINFO for randomized controlled trials (RCTs) from inception to December 2025. Eight RCTs comprising 636 participants were included. Facial BoNT/A injection was associated with a significant reduction in depressive symptoms compared with control conditions (SMD = -0.81; 95% CI, -1.23 to -0.38; p < 0.001). Subgroup analysis revealed that BoNT/A was superior to placebo (SMD = -1.04) and demonstrated efficacy comparable to sertraline (SMD = -0.23). Regarding injection strategies, while standard glabellar protocols demonstrated significant antidepressant efficacy, the high-dose pan-facial subgroup showed no statistically significant difference compared to controls. Anxiety scores did not differ significantly between groups. While overall adverse event rates were similar to controls (RR = 1.04), BoNT/A was associated with transient local reactions, avoiding the systemic side effects observed with sertraline. Facial BoNT/A injection represent an effective, safe treatment for depression. These findings provide valuable insights into a non-systemic therapeutic alternative, particularly for patients intolerant to oral antidepressants or those with polypharmacy burdens. PROSPERO REGISTRATION NUMBER: CRD420261277524.

PubMedInternational journal of microbiology2026-08-30

Distinct Tissue Localization and Transcriptional Profiles of Shiga Toxin-Producing Escherichia coli With and Without the Locus of Enterocyte Effacement at the Bovine Recto-Anal Junction.

Méndez Diego D, Cartajena José T JT, Flores Jacqueline J, Quintanilla Fernanda F et al.

Shiga toxin-producing Escherichia coli (STEC) colonizes the bovine recto-anal junction (RAJ), a key step in STEC pathogenesis in cattle, associated with animal disease, persistence, fecal shedding, carcass contamination, and zoonotic transmission. However, early adhesion mechanisms at the bovine RAJ remain insufficiently characterized, particularly among serotypes lacking the Locus of Enterocyte Effacement (LEE), referred to as LEE-negative strains. This study investigated strain-dependent epithelial interaction patterns at the bovine RAJ using complementary in vitro, ex vivo, and transcriptional approaches. Four representative strains were selected for functional assays, including two LEE-positive strains (O157:H7 and O26:H11) and two LEE-negative strains (O113:H21 and O130:H11). All strains adhered to primary bovine RAJ squamous epithelial cells, although no significant quantitative differences were detected among strains. In RAJ explants, however, LEE-positive strains showed epithelial association extending beyond the superficial layer, with immunolabeling distributed across the epithelial regions, whereas LEE-negative strains showed a predominantly superficial distribution. This pattern, not previously described in bovine RAJ explants, expands the current view of STEC colonization as a uniformly superficial epithelial process. Analysis of selected adhesion-related genes revealed strain-dependent transcriptional responses to the RAJ environment. LEE-positive strains showed higher expression of eae, together with increased expression of iha, csgD, and pgaA. In contrast, LEE-negative strains showed lower expression of these genes and consistent expression of saa, supporting the existence of distinct epithelial interaction strategies that may reflect strain-specific behaviors among circulating LEE-positive and LEE-negative isolates. Overall, these findings demonstrate distinct epithelial interaction and transcriptional profiles among STEC strains and show that physiologically relevant tissue models can reveal serotype-dependent colonization patterns not fully captured in simplified cell systems and may support the identification of potential targets for vaccine-based intervention strategies in cattle.

PubMedNational science review2026-08-30

Direct synthesis of p-type PbS quantum dot inks toward wafer-scale SWIR imaging.

Liu Yang Y, Ma Shengyu S, Deng Chengjie C, Liu Chunmeng C et al.

PbS quantum dots (QDs) are highly promising for scalable short-wave infrared (SWIR) optoelectronics due to their tunable bandgap and solution-processability. While efficient devices require well-defined p-n homojunctions, the fabrication of p-type QD layers remains a critical bottleneck compared with the well-established n-type QD inks. Current fabrication of p-type QD layers relies on solid-state ligand exchange (SSLE). However, SSLE suffers from incomplete ligand replacement and non-uniform oxidation, causing film inhomogeneity that prevents wafer-scale manufacturing. Here, we report a direct synthesis of p-type PbS QD inks with tunable QD size, optical absorption, and p-type electronic characteristics. The resulting inks yield conductive p-type films on 6-inch Si substrates with highly uniform thickness. Using this strategy, we realize SWIR photodetectors with fully ink-processed PbS QD p-n junctions, together with a prototype imaging module. When integrated with a recognition algorithm, the imager provides SWIR images that facilitate vehicle recognition under foggy conditions. This work establishes a scalable route toward future high-performance, wafer-level SWIR optoelectronic platforms.

PubMedTherapeutic advances in gastroenterology2026-08-30

Prevalence of dysphagia and eosinophilic esophagitis in patients with inflammatory bowel disease or type 2 inflammation: a cross-sectional multicenter screening study.

Bäuerle Martin M, Maurer Jurij J, Pokryszka Jagoda J, Novacek Gottfried G et al.

Eosinophilic esophagitis (EoE) is a chronic, type-2 inflammation-driven disease causing dysphagia. Although patients with other type-2 inflammatory diseases (type-2 ID) or inflammatory bowel disease (IBD) may have an increased risk of EoE, there is limited information about the prevalence of EoE in these specific populations. This study aims to assess the prevalence of clinically relevant dysphagia as well as underlying EoE in patients with type-2 ID or IBD. This is a cross-sectional, multicenter study of patients with type-2 ID (asthma, rhinosinusitis with polyposis nasi, allergic rhinitis, atopic dermatitis, Immunoglobulin E (IgE)-mediated food allergies) or IBD from the Medical University of Vienna and Floridsdorf Allergy Center. Patients were screened for esophageal dysphagia using the Brief Esophageal Dysphagia Questionnaire (BEDQ). Relevant dysphagia was defined as a BEDQ score ⩾4, or having a history of bolus impaction or emergency department visit due to dysphagia within the past year. Endoscopy with esophageal biopsies was offered to all patients with relevant dysphagia to screen for EoE. A total of 687 patients (45.9% female, median age 45 years, 53.9% with IBD, 48.5% with a type 2 ID) were screened. Overall, 8.9% (n = 61) reported relevant dysphagia. Endoscopy with biopsies was performed in 22 patients, and 18 patients had undergone endoscopy the year prior to the study. In total, 6 newly diagnosed cases of EoE were observed, while 7 patients had a known history of EoE, resulting in an overall prevalence of 13 patients (1.9%). Patients with any type-2 ID had numerically more EoE (2.7%) than patients with IBD (1.9%). While the prevalence of dysphagia among patients with type-2 ID and IBD may not exceed that of the general population, the prevalence of EoE in these populations may be higher than previously recognized.

PubMedMedical mycology journal2026-08-30

Inflammatory-Type Tinea Corporis from Trichophyton mentagrophytes Animal Type 3 with Suspected Infection from a Guinea Pig.

Hosoi Misato M, Tsuchihashi Hitoshi H, Hiruma Masataro M, Taguchi Nobuyuki N et al.

An adlescent girl was bitten on the right middle finger while attempting to intervene in a fight among her three pet guinea pigs. She was initially treated by a local physician without improvement and was subsequently referred to the Department of Dermatology at our hospital. Direct microscopic examination of scales and crusts with KOH was positive, and she was diagnosed with tinea corporis. The isolated fungus was morphologically identified as belonging to the Trichophyton mentagrophytes complex, and topical luliconazole cream was administered. Molecular analysis based on the DNA sequence of the nuclear ribosomal internal transcribed spacer (ITS) 1 region revealed that the isolate belonged to ITS type II, corresponding to T. mentagrophytes animal type 3. These findings strongly suggested zoonotic transmission from the pet guinea pigs. This appears to be one of the very few reported cases of T. mentagrophytes animal type 3 isolated from a human lesion.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about botulinum toxin type A